Patients with mesothelioma may be getting a new second-line treatment, thanks to results from a recent immunotherapy trial. For patients with malignant pleural mesothelioma — which makes up about 90 ...

Doctors at the Mesothelioma Treatment Center at Baylor College of Medicine and Baylor St. Luke’s Medical Center are now offering mesothelioma patients a new FDA-approved device as part of their ...

WASHINGTON – People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the ...

Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to SynKIR-110, an investigational chimeric antigen receptor T-cell ...

NET of the lung: The experience of the Italian registry. Clinical features in surgically treated patients with small cell lung cancer: Risk of brain metastasis and possible role of prophylactic ...

John Comerford, senior partner of Lipsitz, Ponterio & Comerford says when people come to see them with mesothelioma, they have to do a little type of investigation to determine how they were exposed ...

A novel treatment for advanced mesothelioma is safe and effective and may improve the quality of life for patients who have few treatment options, according to new research. Transarterial ...

Receiving a mesothelioma diagnosis overwhelms the individual with health problems and Nagging questions that follow. Most ...

Malignant pleural mesothelioma (MPM) is a primary and locally aggressive tumor of the pleura. A well defined causal relationship with asbestos exposure, and an overwhelming media interest in the use ...